Sight Sciences' analysis shows TearCare can save health plans $36.87 PMPY over traditional dry eye treatments in the U.S. Results from a Budget Impact Analysis indicate that a 20% increase in market ...
The expenditure of the Dutch health care system between 2017 and 2025 associated with the introduction of HIPEC for patients with stage III ovarian cancer eligible for interval CRS (target population) ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
Humacyte, Inc. announced the publication of a Budget Impact Model for its bioengineered human tissue, Symvess, in the Journal of Medical Economics, indicating its cost-effectiveness for hospitals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results